文献速递外周动脉疾病

整合炎症-代谢模型用于外周动脉疾病严重程度分层

An Integrated Inflammation-Metabolism Model for Stratifying Severity of Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2026-08-19

本研究整合分子、人群和临床数据集,探讨炎症-代谢交互与外周动脉疾病(PAD)严重程度及慢性肢体威胁性缺血(CLTI)的关系。临床队列中构建的CLTI分层模型显示出良好区分度(AUC=0.856),但数据为横断面,需外部前瞻性验证。

要点

  • 炎症与代谢通路在PAD不同阶段协同激活。
  • CLTI分层模型纳入BMI、吸烟、高血压、hs-CRP和TyG,AUC=0.856。
  • 模型应视为CLTI风险分层工具,非纵向预测证据。

核心结论

  • 炎症-代谢交互与PAD严重程度及CLTI状态相关。
  • 因数据为横断面,模型应解读为CLTI风险分层工具而非纵向疾病预测证明。
  • 临床实施前需外部前瞻性验证。

研究设计与样本

  • 研究整合公共基因表达谱、NHANES数据及单中心临床队列。
  • 公共基因表达谱比较间歇性跛行与CLTI、健康对照与PAD。
  • NHANES数据评估指标与ABI定义PAD的关联,但无法可靠区分PAD严重程度。
  • 单中心临床队列比较对照、无CLTI的PAD和CLTI,并构建CLTI分层模型。
  • 变量经LASSO回归选择后纳入多变量logistic回归。

主要发现

  • 炎症和代谢通路在疾病阶段比较中显示协同激活。
  • NHANES中TyG、NLR、SIRI和AISI在单变量分析与ABI定义PAD相关。
  • 临床队列中NLR、SII、TyG和AISI从对照到无CLTI的PAD再到CLTI逐渐升高(均P < 0.001)。
  • qRT-PCR证实关键基因逐步上调。
  • 多变量分析识别无CLTI的PAD相关因素为hs-CRP、TyG和AISI,CLTI相关因素为BMI、吸烟、高血压、hs-CRP和TyG。

关键数值与推荐

  • CLTI分层模型区分度AUC=0.856。
  • 临床队列中NLR、SII、TyG和AISI组间比较均P < 0.001。

临床怎么用

  • 该模型可用于PAD患者中CLTI风险分层,辅助识别高风险个体。
  • 模型变量包括BMI、吸烟、高血压、hs-CRP和TyG,均为临床可测量指标。
  • 临床使用前需等待外部前瞻性验证结果。

局限性

  • 可用数据为横断面,无法证明纵向预测能力。
  • NHANES数据无法可靠区分PAD严重程度。
  • 模型需外部前瞻性验证后方可临床实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral artery disease (PAD) encompasses a spectrum ranging from asymptomatic disease and intermittent claudication to chronic limb-threatening ischemia (CLTI). Inflammation and metabolic disturbance are increasingly recognized as interconnected features of atherosclerotic disease, but their combined relationship with CLTI status in PAD remains incompletely defined. This study investigated inflammation-metabolism interactions across molecular, population-level, and clinical datasets and developed a clinically applicable model for CLTI risk stratification among patients with PAD. METHODS: Public gene expression profiles were used to compare intermittent claudication with CLTI and healthy controls with PAD, focusing on inflammation-related and metabolism-related pathways. These molecular signals were then mapped to clinically measurable indices. The National Health and Nutrition Examination Survey (NHANES) data were used to evaluate associations between these indices and ankle-brachial index (ABI)-defined PAD at the population level; NHANES did not permit reliable subclassification of PAD severity. A separate single-center clinical cohort was used to compare controls, PAD without CLTI, and CLTI and to build a CLTI stratification model. Variables were selected by least absolute shrinkage and selection operator regression and reintroduced into multivariable logistic regression. Model performance was assessed using the area under the receiver operating characteristic curve, calibration, and decision curve analysis. RESULTS: Inflammatory and metabolic pathways showed coordinated activation across disease-stage comparisons. In NHANES, the triglyceride-glucose index (TyG), neutrophil-to-lymphocyte ratio (NLR), systemic inflammation response index, and aggregate index of systemic inflammation (AISI) were associated with ABI-defined PAD in univariate analyses. In the clinical cohort, NLR, systemic immune-inflammation index, TyG, and AISI increased from controls to PAD without CLTI and CLTI (all P < 0.001), while qRT-PCR confirmed stepwise upregulation of key genes. Multivariable analysis identified high-sensitivity C-reactive protein (hs-CRP), TyG, and AISI for PAD without CLTI, and BMI, smoking, hypertension, hs-CRP, and TyG for CLTI. The CLTI stratification model demonstrated good discrimination (area under the curve = 0.856). CONCLUSION: Inflammation-metabolism interactions are associated with PAD severity and CLTI status. Because the available data are cross-sectional, the model should be interpreted as a CLTI risk stratification tool rather than proof of longitudinal disease prediction. External prospective validation is required before clinical implementation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gao Q, Shen Y. An Integrated Inflammation-Metabolism Model for Stratifying Severity of Peripheral Artery Disease. Ann Vasc Surg. 2026. PMID: 42617690. doi:10.1016/j.avsg.2026.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。